Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    14657698 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Condition: Kidney Failure, Chronic
Intervention: Biological: Immune Globulin Intravenous (Human), 10%

Indicates status has not been verified in more than two years